Madrigal Pharmaceuticals
MDGL
31 hedge funds and large institutions have $12.8M invested in Madrigal Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 21 reducing their positions, and 26 closing their positions.
35% more capital invested
Capital invested by funds: $9.44M → $12.8M (+$3.33M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
44% less funds holding
Funds holding: 55 → 31 (-24)
59% less call options, than puts
Call options by funds: $26K | Put options by funds: $63K
76% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 21
88% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.11M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$610K |
| 3 |
Goldman Sachs
New York
|
+$43.3K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31.8K |
| 5 |
JP Morgan Chase
New York
|
+$853 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$1.12M |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$98K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$85K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$79.4K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$69K |
MDGL Hedge Fund Activity: Q3 2016 in Review
31 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2016, worth a combined $12.8M — up 35% from $9.44M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MDGL and 3 opened new positions — a net loss of 23 holders — while 21 trimmed existing stakes and 5 added.
The largest buyer was Armistice Capital, adding an estimated $1.11M. The largest seller was Caxton Corporation, cutting an estimated $1.12M.
- 31 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2016, down from 55 in Q2 2016.
- Funds reported $12.8M of Madrigal Pharmaceuticals stock for Q3 2016, up 35% quarter-over-quarter.
- 3 funds opened new Madrigal Pharmaceuticals positions in Q3 2016 and 26 closed out, a net change of -23 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2016 was Armistice Capital, an estimated $1.11M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2016 was Caxton Corporation, an estimated $1.12M sold.
Based on aggregated 13F filings for Q3 2016.